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Abstract
Background: The term evidence based medicine was introduced in the early 1990s in clinical medicine to educate
clinicians about how to assess the ‘credibility’ of research to ensure best treatments for their patients. The evidence
based medicine paradigm has become more diffuse in times of austerity and randomised controlled designs are
being used to address complex issues in public health and disability research. This research is not addressing
inequalities in terms of disability nor how people can live well with disabilities.
Main text: We argue that there are four ways that public health research needs to change if it wants to address
inequalities linked to disability: 1) rethinking theoretical connections between public health and disability; 2)
building ethics and equity into interventions through a human rights approach; 3) ensuring ethical inclusion
through intersectionality; and 4) evaluating policy and other social impacts to ensure they capture diversity. We
argue that these are key issues to building a social determinants of flourishing.
Conclusions: We need to understand how disability might have an accumulative impact across the life course, as
well as how to ensure equity for people living with disabilities. This means conceptualising a social determinants of
flourishing where we evaluate how exactly randomised controlled trials and public health interventions, not only
lead to greater equality but also ensure rights to health and wellbeing.
Keywords: Public health, Disability, Intervention, Evidence, Policy, Flourishing
Background
Evidence based medicine, public health and policy-
making
The term evidence based medicine (EBM) was intro-
duced in the early 1990s in clinical medicine to educate
clinicans about how to assess the ‘credibility’ of research
to ensure best treatments for their patients [1]. British
Centres for Evidence were established and it was taken
up into clinical training, textbooks and practice. EBM
was also espoused as new paradigm in 2001 by the
Cochrane Collaboration, which publishes rigourous
methodological information about clinical randomised
controlled trials (RCTs) [2]. It was hoped that the EBM
paradigm would ensure that clinical practices would
become ‘scientfic’, in the sense of giving assurances of
quality of scientific background and emprical research to
inform clinical decisions, as well as evidencing value for
money by ensuring clinicians did not pursue treatments
that did not work [3].
Djulbegovic and Guyatt [1] argue that there are three
epistemological principles for EBM: firstly that evidence
has to be trustworthy, credibly determined and based on
controlled clinical observatons; secondly that the ‘total-
ity’ of evidence should inform the truth of decisions; and
thirdly, that ‘clinical decision-making requires consider-
ation of patients’ values and preferences’. In order to
assess such principles, evidence hierarchies began to ap-
pear; with critical appraisals assuming that clinical RCTs
provided more certainty than uncontrolled emprical
studies, while systematic reviews (using evidence synthe-
sis) were developed to measure the ‘totality’ of evidence.
Parallel systems in the United States (US) have also
evolved and numerous standards and guidelines have
been developed to ensure better evaluations, as well as
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designs for RCTs. There has been a focus on what
‘works’ in terms of RCTs and then understanding ‘why’
in terms of their evaluation. Robust methodological
guides are now emphasised in checklists, like the Con-
solidated Standards of Reporting Trials (CONSORT) [4].
In the United Kingdom (UK), the EBM paradigm has
been espoused through the National Institute for Health
and Care Excellence (NICE), who highlight the improve-
ment of health and social care through evidence-based
guidance. Implementation science has also been advo-
cated by the National Health Service (NHS) to try and
close the gap between research and practice, by evaluat-
ing ‘why’ interventions work.
In times of neoliberalism and austerity, it can seem as
if the EBM framework is becoming more diffuse and
applied to a much broader range of decisions [5], in line
with an increasing emphasis being placed on evidence
for budget allocations and justfications of how funding
is being spent. Trial evidence has, therefore, become
especially attractive to policy makers as it seems to offer
potential solutions to complex, expensive and increasing
politically contested dilemmas facing health care,
thereby meeting ‘a longing that this rational discourse
can in Rousseauian fashion locate and unmask our
suffering’ [6]. This explains why the principles of EBM
have spread, from being used to weigh up evidence for
health interventions in clinical practices, to wider realms
such as public health, social prescribing and even eco-
nomic policy making. For example, the UK’s What
Works Network was formed in 2014 as a government
intiative that promotes the use of robust evidence to
faciliate policy making and service delivery, in areas as
diverse as health, policing and development aid [7]. This
means, for instance, the UK’s Department for Inter-
national Development (DFID) has to ensure that their
policy teams can illustrate how decision making is evi-
dence-based and this is inclusive of business decision-
making [7]. While Greenhalgh et al. [3] and Wieringa et
al. [5] have been critical of the misappropriation of the
EBM brand, they also offer solutions, viewing EBM as a
‘situated practice’ in terms of links to how cultural values
and norms influence ‘evidence’. This points to a trickier
issue, in that while the policy focus is on what ‘works’, its
evaluation and ‘why’ an intervention works becomes
more complex in different global contexts.
In terms of public health, Victora et al. [8] too warn
that application of EBM to research means that we have
to become more critical and think beyound simplistic
RCT designs. Similarly, Mays et al. [9] note that despite
the fact that policy-makers are under increasing pressure
to adopt evidence-based decisions, Cochrane style re-
views of evidence alone will not be enough and different
approaches might have to be evaluated. This indicates
that issues with EBM are not only located within
research but also policy making, affecting interventions
and the evaluation of research evidence [10], for ex-
ample in terms of implementation science, as well as its
further funding. In this paper, we want to focus on the
links between RCTs and public health to see if any evi-
dence-based innovations are possible in terms of
disability research.
RCTs are currently regarded as the gold standard for
scientific evidence in public health policy, with gaps
between research and policy uptake still viewed as prob-
lematic [11, 12]. We accept that RCTs in public health
have a crucial part to play in ensuring the health of
people who have disabilities across the life-course.
Evidence from RCTs can lead to interventions that can
tackle underlying causes of ill-health and reduce health
inequalities with the potential to transform lives and en-
sure rights to independent living [13]. Yet, in a letter in
The Lancet, van der Marck et al. [14] note that the
biggest challenge that clinicians will face in the next
twenty-five years, is patients presenting with multi-mor-
bidities across the life-course for whom evidence
informed guidelines will not work and may cause harm.
They argue that there is a ‘fundamental mismatch’ be-
tween evidence being produced and what will be needed
to tackle disabilities [14]. We argue that this mismatch
in terms of disability is also present in public health, and
linked to the kind of research that is being funded and
its evaluation. This raises broader challenges in how
evidence is presented and interpreted.
First, evidence synthesis reinforces the clinical basis of
medicine, to the relative neglect of social-economic,
cultural and environmental conditions [15], while simul-
taneously struggling to engage with the meaning patients
and practitioners’ accord to an intervention [16]. Conse-
quently, key contextual factors contributing to the
broader social determinants of health - and the success
or otherwise of an intervention - are underplayed [14].
Second, synthesis often assumes the idealised integrity of
trial methodology, rather than offer a critical account
of how the trial was conducted, designed and re-
ported [17, 18]. Over 50 % of trial interventions, for
example, are inadequately described and over 50 % of
planned study outcomes not reported, with negative re-
sults rarely getting published [19]. Moreover, randomisa-
tion rarely provides representative samples, specifically
failing to address diversity, in terms of age, sexuality, eth-
nicity or disability [13]. Third, a narrow focus on trial
evidence has meant equally valuable forms of insight, such
as those offered by epidemiology, are neglected [20]. Epi-
demiology has a particularly strong tradition of reflecting
the experience of those traditionally neglected by trial evi-
dence [21], and is also able to embrace the challenges
posed by future of epigenetics [22]. Finally, the focus of
trials, can obscure the role of political decision-making
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and bias in determining the evidence available or
what evidence is regarded as significant and/or put
into practice [23].
Despite decades of research advocating synergies
between public health and disability research [24, 25],
we know little about how disabled people and disability
theory are integrated into public health RCTs. Previous
studies have mostly recorded exclusions and non-re-
cruitment of disabled population groups most affected
by health inequalities, for example, people with intellec-
tual disabilities [26–28]. We thus want to begin a critical
theoretical and empirically informed discussion about
the ways in which public health RCTs could better inte-
grate disability. Furthermore, we argue that public health
RCTs now need to take into account issues of policy
impact, as well as health inequalities, which focus on en-
suring not only that people can live well with disabilities
but that they have a right to that health. This entails
thinking more constructively, in practical terms, about
how we are integrating human rights and social justice
perspectives in inequalities research so we guarantee
social flourishing with disabilities. Our approach is
consistent - at least in spirt - to the intent of Doll &
Bradford-Hill [29], who in establishing the scientific
basis of current trial methodology, were suspicious of
naïve descriptive empiricism, particularly when it was at
the expense of more theoretically informed enquiry. We
argue for a novel social determinants of flourishing,
which is more consistent with how people experience
disability, within an evidence-based framework that
places an emphasis on RCTs and their evaluation. There
are four ways in which this can be achieved by: 1)
Rethinking theoretical connections between public
health and disability; 2) Building ethics and equity into
interventions through human rights; 3) Ensuring ethical
inclusion through intersectionality; and 4) Evaluating
policy and other social impacts. We explain each in
turn.
Social flourishing with disabilities
Rethinking theoretical connections between public health
and disability
In a commissioned National Institute for Health Re-
search - Public Health Research (NIHR-PHR) study on
the implications of disability for public health RCTs, we
did a global scoping review of 30 specific public health
systematic reviews as well as 30 generic systematic
reviews of RCTs found in the Cochrane database. We
evaluated these reviews through a disability rights frame-
work and we found that there had been limited public
health engagement with the theories and models of both
public health and disability [13]. Theory based RCTs and
their efficacy have received increasing public health
attention in terms of explaining the outcomes of
interventions [30, 31]; theoretical disconnects of RCTs
to disability theories and models much less so. These
theoretical disconnections between the public health
paradigms that are being espoused in RCTs and actual
research involving disability should get more critical
attention [32]. If we examine the need for theoretically
informed RCTs, we note that there has to be a greater
theoretical public health engagement with personal
values and ethical norms of disabled people, as well as
theory found in disability studies literature.
We argue that disability theory should be central to
the design of RCTs undertaken by public health re-
searchers, as well as their critical evaluations and thus
incorporated in systematic reviews. Da Silva et al. [33]
argue that, for increasingly complex prospective inter-
ventions, more rigorous theoretical approaches to inter-
vention design are needed. However, to understand why
interventions are working either upstream or down-
stream also requires critical theoretical evaluation of the
epistemological and ontological foundations of public
health and disability RCTs. Why particular RCT designs
being chosen over others, and do they work in practical
terms? Are they cost-effective short and long term; and
what frameworks are being used to make those judge-
ments about cost-effectiveness? Are the best public
health and disability RCT designs necessarily complex?
Why and when do explanatory or pragmatic designs
work?
To answer these questions, some authors advocate
using realist approaches when evaluating public health
RCTs [34, 35], and some even when designing interven-
tions in general [36]. This could connect well with the
theoretical and methodological basis of disability models
and with more holistic, complex and ecological under-
standings of public health [13, 37]. Such approaches
could also offer a critical commentary on what questions
get asked in the first place, alongside how studies are
conducted and findings interpreted. Another way in
which to evaluate and rethink the way in which we
design public health and disability RCTs, would be to
use human rights as a bridge.
Building equity into RCT design and evaluation through
human rights
Human rights frameworks or approaches often use ‘per-
sons first’ definitions and aim to establish legal, political,
cultural, social and economic rights for all people [13].
Human rights theories can provide a unifying framework
or bridge between public health, and disability theories
and models, to ensure equity [38]. Despite the potential
of human rights frameworks, we found that they have
been somewhat neglected in RCTs in terms of design
and evaluation [13]. This is despite a general trend
among institutions, such as the World Health Organization
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(WHO) and United Nations (UN), in adopting human
rights indicators, frameworks, measurements of health
capabilities and health equity monitoring to evaluate inter-
ventions in general.
Rights-based approaches are also increasingly being
used in terms of RCT design as well as evaluations of
public health and disability interventions [27, 39]. Hu-
man rights and equality frameworks are advocated in
terms of social protection and to safeguard entitle-
ments and rights to health. We also found that there
was not only a political and social acceptance of
human rights frameworks amongst people with
disabilities in the UK but also advocacy for greater
enforcement in all areas of life, including public
health research [40]. While human rights frameworks,
and in particular the United Nations Convention on
the Rights of Persons with Disabilities (CRPD) [41] is
often mentioned in research, how to operationalise
such rights to be used in design and evaluative tools
in RCTs and general public health interventions has
been under theorised. Notwithstanding the fact that
there is a greater need to think about not only how
to gather evidence of public health impact on health
inequalities [42] but now also assurances of rights of
people affected [40].
Human rights frameworks are also in keeping with
critical disability theories that destabilise the norms of
rational choice theory and emphasise the social causes
of health inequalities rather than ‘checking’ the health
effects of RCTs. Furthermore, this is consistent with
public health paradigms that advocate complexity and
innovation, and as such could be easily taken up into
guidelines that evaluate RCT designs and interventions.
The CRPD in particular, encapsulates that health is
about more than medical access and disability results
‘from the interaction between persons with impairments
and attitudinal and environmental barriers that hinders
their full and effective participation in society on an
equal basis with others’ [41].
Ensuring ethical inclusion through intersectionality
In terms of equity, Schulz et al. [4] note that a weakness
in checklists like CONSORT is that they do not record
that information. Yet, equity can be easily integrated and
considered in consultation, design and impact of RCTs.
This is especially important in public health, when RCTs
are designed in response to health inequalities amongst
marginalised population groups, for example, disabled
people. To overcome this difficulty, we introduce the
idea of design and evaluation of equity within interven-
tions through the use of disability theory and human
rights frameworks. Research indicates that social justice
in terms of impact of RCTs, is now also becoming linked
to greater inclusion for disabled people [40]. Inclusion
would also involve intersectionality of disability to age,
sexuality, ethnicity, gender, socio-economic status and
co- or multi-morbidities. However, we think intersec-
tionality has to be broader than this to ensure ethical
inclusion.
A next step, in terms of inclusion and an intersectional
approach, would be to evaluate equity downstream, in
terms of impact of an RCT not just on policy but in
terms of developing an understanding of individual,
socio-political, economic and environmental impacts on
disability, such as via the social determinants of health
[43]. Humphreys and Piot [44] have argued that
scientific evidence alone is not a sufficient basis for
health policy. We would argue that political legitimation
of policy weakens without a link to empirically and
theoretically robust science.
Liverani et al. [45] note that there has been ‘limited ex-
plicit engagement with relevant theories in the literature
on evidence-informed health’ and they argue more
research on bias and policy uptake of evidence-based re-
search is needed. Recognising the broader determinants
(individual, social, political and economic) of health
could facilitate more inclusive research practices and
allow researchers to locate an individual’s intersectional
and epi-genetic experiences within their social environ-
ment [42]. Thus equity upstream and downstream of
RCTs would have to be assured in terms of inclusion
and intersectionality.
Evaluating policy and other social impacts
The uptake of evidence of RCTs into generalised public
health interventions and their evaluations is the respon-
sibility of public health policy makers, commissioners or
providers. This involves political decision making.
Similarly, the funding priorities and research that is
being commissioned is decided by political require-
ments, understanding of health priorities and policy
trends. RCTs are viewed as a gold standard in terms
of influence on policy but within public health and
disability research it would be useful to ensure a
means of ‘social accountability’ through evaluation of
improvement or attainment of disability rights or ac-
quisition of rights by disabled people during and after
a RCT [46]. Within public health research, and imple-
mentation science in particular, there have been many
suggestions to develop conceptual frameworks to
evaluate equity in RCT designs [47] but there is no
main standard or guideline that is being used. Like-
wise, within policy-making there is no standard guide-
line for assessing the social impacts of a public health
intervention and no real links to equity similar to, for
instance, the National Health Services (NHS) Equality
Analysis and Impact Assessments. We argue that im-
pacts and assessments in both RCT research design
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and intervention studies have to move beyond equity
and inequalities, towards understanding if people’s
rights to social determinants of flourishing are being
respected.
This means that the focus would also shift from influ-
encing policy to understanding social policy impacts, for
example, on rights entitlements or people with protected
characteristics. This is about more than ensuring equity
or assessing inequalities. We argue that RCTs would
have to integrate evaluations of equity and translation of
equity indicators, or measures that aligned with public
health and disability theory, for example, and this would
translate into evaluating how ‘enabling’ a public health
RCT was to both the short and long-term sustainability
of wellbeing of people with disabilities. Another means
of understanding public health wellbeing or equity
would be to examine the capabilities that people had
before and after a public health intervention and if they
were able to sustain, live well or ‘flourish’ with impair-
ment(s) [48].
In terms of conceptualising what a more equitable
public health and disability paradigm shift would in-
clude, we contend that an evaluation of how people
flourish or thrive is consistent with both public health
and disability theories and models. Rather than concep-
tualising disability in terms of burden, cost, reduced
functioning or viewing aging as a problem to public
health, we feel that we could advocate a more holistic
understanding by focusing on social and environmental
impacts. Such an understanding would take a different
ontological and epistemological approach to equity in
public health, in terms of shift to a social measurement
of not only right to health or capability for health but
also a conceptualisation of how RCTs and interventions
aid people with disability, chronic illness and impair-
ment to live well across the life-course. The understand-
ing of ‘flourish’ is different from those developed in
terms of ‘capabilities’ because it encompasses elements
of distinction, which are connected to social and polit-
ical empowerment.
This would encompass a finer attunement to the im-
pact of ill health as well as disabling experiences and
environments. So, an evaluation could be translated in
terms of measures of how and if public health interven-
tions had an impact on social status or standing, envir-
onmental accessibility or political emancipation and how
sustainable this proved to be [49]. Most measures and
indicators that have been developed either work in a
specific disability model [48] or have not engaged public
health alongside disability. We are arguing that evalua-
tions within RCTs examining equity or assessing outcomes
of interventions should focus on social determinants of
flourishing for people with disability and impairment
across the life-course.
Conclusion
Disability is a continuous process and everyone is likely
to be affected by ill health, impairment and disability
across the life-course as they age and people with dis-
abilities are living longer. Yet, the inequalities affecting
disabled people living in poverty, disabled children, and
those with intellectual and complex disabilities mean we
have more and better work to do. There are now over
10 million people who face ‘limitations in daily activities’
in the UK and disability is found more in areas of
greater social disadvantage [50]. Epidemiologically, dis-
ability is also linked to illness and disease across the life
course with extra needs corresponding to impairment
and co-morbid conditions [51]. From a public health
perspective, disabled people are disadvantaged in all
aspects of their life: from socio-economic environments
in which they live to lack of access to quality housing;
education; transport; and health and social care services
- this has a cumulative affect across the life-course [52].
Research has found reduced life expectancy among
people with intellectual disabilities and those with men-
tal health conditions. For instance, Heslop et al. [53], in
their confidential inquiry, reported that men with intel-
lectual disabilities die 13 years earlier and females 20
years earlier than the general population. The social de-
terminants of mental health of people with intellectual
disabilities, has also been correlated with ‘poorer living
conditions’ rather than ‘impairment per se’ [54].
Evidence found higher rates of hospitalisations [55] and
increases in mortality rates [56] but also that public
health interventions could be focused to better aid this
under-served population group [57].
We need to understand more about how disability
might have an accumulative impact across the life
course, as well as how epidemological factors like epi-
genetics play a role in understanding equity. We argue
that an evidence-base focused on how to flourish with
disability would provide those answers. RCTs and inter-
ventions can become more ethical and empirically
robust by reconceptualising inclusion of public health
with disability theory as well as include disabled people
in making those changes, enabling everyone to live well
and flourish. This means conceptualising a social deter-
minants of flourishing where we evaluate how exactly
RCTs and public health interventions, not only lead to
greater equality but also ensure rights to health and
wellbeing.
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